Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
B129831-10mg | 10mg | In stock | $76.90 | |
B129831-50mg | 50mg | In stock | $253.90 | |
B129831-100mg | 100mg | In stock | $406.90 | |
B129831-500mg | 500mg | In stock | $1,424.90 | |
B129831-1g | 1g | In stock | $2,279.90 |
Synonyms | AGN 192024 | (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(S,E)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide | 17-Phenyltrinor-PGF2α Ethylamide |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Bimatoprost is converted by an amidase enzymatic activity in bovine and human cornea models to yield the corresponding free acid, 17-phenyl trinor PGF2α, a potent PGF2αR agonist. In human and animal models of glaucoma, FP receptor agonist activity corresp |
Storage Temp | Protected from light,Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Prostanoid FP receptor agonist |
Note | 10mg卖完停产,不再备货 |
Product Description | Bimatoprost is a prostaglandin analogue that can be used in studies of ocular hypertension and glaucoma and also has anti-fat formation effects
|
ALogP | 2.8 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide |
---|---|
INCHI | InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1 |
InChi Key | AQOKCDNYWBIDND-FTOWTWDKSA-N |
Canonical SMILES | CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O |
Isomeric SMILES | CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O |
WGK Germany | 3 |
PubChem CID | 5311027 |
Molecular Weight | 415.57 |
PubChem CID | 5311027 |
---|---|
DrugBank Ligand | DB00905 |
CAS Registry No. | 155206-00-1 |
Wikipedia | Bimatoprost |
ChEBI | CHEBI:51230 |
ChEMBL Ligand | CHEMBL1200963 |
RCSB PDB Ligand | 15M |
PEP | bimatoprost |
DrugCentral Ligand | 371 |
GPCRdb Ligand | bimatoprost |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
F2228092 | Certificate of Analysis | Apr 03, 2024 | B129831 |
F2228094 | Certificate of Analysis | Apr 03, 2024 | B129831 |
F2228095 | Certificate of Analysis | Apr 03, 2024 | B129831 |
F2228096 | Certificate of Analysis | Apr 03, 2024 | B129831 |
E2414209 | Certificate of Analysis | Apr 01, 2024 | B129831 |
E2414211 | Certificate of Analysis | Apr 01, 2024 | B129831 |
E2414212 | Certificate of Analysis | Apr 01, 2024 | B129831 |
B2421158 | Certificate of Analysis | Jan 09, 2024 | B129831 |
H2321379 | Certificate of Analysis | Aug 10, 2023 | B129831 |
G23211127 | Certificate of Analysis | Jun 28, 2023 | B129831 |
G23211199 | Certificate of Analysis | Jun 28, 2023 | B129831 |
G23211172 | Certificate of Analysis | Jun 28, 2023 | B129831 |
G23211156 | Certificate of Analysis | Jun 28, 2023 | B129831 |
G23211153 | Certificate of Analysis | Jun 28, 2023 | B129831 |
G23211148 | Certificate of Analysis | Jun 28, 2023 | B129831 |
G23211147 | Certificate of Analysis | Jun 28, 2023 | B129831 |
G23211144 | Certificate of Analysis | Jun 28, 2023 | B129831 |
G23211141 | Certificate of Analysis | Jun 28, 2023 | B129831 |
G23211135 | Certificate of Analysis | Jun 28, 2023 | B129831 |
G2311156 | Certificate of Analysis | Jun 28, 2023 | B129831 |
I2110027 | Certificate of Analysis | Jun 15, 2023 | B129831 |
G1527040 | Certificate of Analysis | Feb 06, 2023 | B129831 |
F2228093 | Certificate of Analysis | May 31, 2022 | B129831 |
G2027130 | Certificate of Analysis | May 10, 2022 | B129831 |
Solubility | Soluble in ethanol (~50 mg/ml), methanol, DMSO (~25 mg/ml), DMF (~25 mg/ml), and PBS (pH 7.2) (~300 ug/ml). |
---|---|
Sensitivity | Air Sensitive,Heat Sensitive |
Specific Rotation[α] | 35° (C=1,MeOH) |
Melt Point(°C) | 75 °C |
Pictogram(s) | GHS08, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H319:Causes serious eye irritation H302:Harmful if swallowed H312:Harmful in contact with skin H360:May damage fertility or the unborn child H340:May cause genetic defects H361:Suspected of damaging fertility or the unborn child |
Precautionary Statements | P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P281:Use personal protective equipment as required. P270:Do not eat, drink or smoke when using this product. P362+P364:Take off contaminated clothing and wash it before reuse. P330:Rinse mouth. P203:Obtain, read and follow all safety instructions before use. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P301+P317:IF SWALLOWED: Get medical help. P318:if exposed or concerned, get medical advice. P317:Get emergency medical help. P337+P317:If eye irritation persists: Get medical help. |
WGK Germany | 3 |
Merck Index | 1221 |
Starting at $274.90
Starting at $67.90
Starting at $95.90
Starting at $50.90
Starting at $57.90
Starting at $236.90
1. Davies SS, Ju WK, Neufeld AH, Abran D, Chemtob S, Roberts 2nd LJ. (2003) Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro.. J Ocul Pharmacol Ther, 19 (1): (45-54). [PMID:12648303] |
2. Camras CB, Sharif NA, Wax MB, Stjernschantz J. (2008) Bimatoprost, the prodrug of a prostaglandin analogue.. Br J Ophthalmol, 92 (6): (862-3; author reply 863-4). [PMID:18523093] |